340B Reforms: Oversight Hearing Suggests Slow, Piecemeal Approach
There appears to be bipartisan interest in beefing up HRSA’s ability to oversee the 340B program – but the next step is likely to be more hearings and fact-finding, not immediate legislative changes.
You may also be interested in...
House Energy & Commerce Committee recommends more oversight of hospital participation in the 340B drug discount program.
House Energy and Commerce Committee Chair Greg Walden, R-Ore., expresses frustration at lack of reliable data on the way providers account for 340B drug discounts at Oct. 11 hearing.
Pew Charitable Trusts' Allan Coukell warns the Centers for Medicare and Medicaid Services that its proposal to reduce Medicare Part B drug payments to 340B hospitals may have 'unintended consequences.'